|
Chairman of the Board
 William
U. Parfet, MBA, joined MPI Research in November 1995
as co-chairman. He has served since May 1999 as Chairman and
CEO of MPI Research. At Richard-Allan Medical, a worldwide manufacturer
of surgical products, he served as President and Chief Executive
Officer from October 1993 to January 1996. Before that, he had
been employed at The Upjohn Company since March 1973. A member
of the Board of Directors from 1985–2003,
he served as Vice Chairman of the Board, President (1991–1993)
and Executive Vice President (1989–1991) of The Upjohn Company.
Mr. Parfet received his BA (with honors) in 1970 from Lake Forest
College with a major in economics and received his MBA in international
finance from the University of Michigan in 1972. Mr. Parfet serves
on various other boards, including CMS Energy Corporation, Monsanto
Company, Parexel International Corporation, Stryker Corporation,
Flint Ink Corporation, and MPI Research.
Board Members
 Chun-Lin
Chen, PhD, serves as the CEO of Medicilon/MPI
Preclinical Research Shanghai. Formally a Staff
for Vertex Pharmaceuticals, Dr. Chen co-founded Medicilon
in 2004. Dr Chen is a highly published thought leader
in the pharmaceutical industry with extensive experience
in academia, pharmaceutical, and regulatory evaluation.
Dr. Chen received his PhD from Oklahoma State University,
and completed postdoctoral training in the United States.
He is a Postdoctoral Fellow at the St. Jude Children’s
Research Hospital and has held numerous leadership positions
in professional scientific trade organizations in China
as well as other parts of the world.
 Bill
Harrison, BS, is President and Chief Operating Officer
of
MPI Research. Before joining MPI Research in 1993, he was Director
of Regulatory Affairs and Operations at Pharmaco LSR (formerly
Bio/dynamics). Mr. Harrison is a member of the MPI Research Corporate
Management Team and the Board of Directors. He holds a BS in
biomedical engineering from the New Jersey Institute of Technology
and has more than 20 years experience in contract laboratories.
 Jintao
Zhang, PhD, is the CEO and co-founder of Shanghai Medicilon
Inc. Prior joining Shanghai Medicilon in 2004, Dr. Zhang was Director
of Combinatorial Chemistry at DeCode Genetics Inc., a genetics and health
informatics company. Prior to DeCODE’s merger with MediChem Life
Sciences in 2002, Dr. Zhang was Director of Combinatorial Chemistry at
MediChem. Dr. Zhang received his PhD in Organic Chemistry from the Shanghai
Institute of organic chemistry. He performed his postdoctoral fellowships
at the University of Chicago.
|
 |
